OBJECTIVES: European payer authorities reimburse the administration of anticancer agents for mNSCLC patients according to diverging tariffs and varying codes. This poses the question of whether there is the need for a sensitivity analysis of administration costs in health economic models when applied in France, Germany, Italy, Spain, and the United Kingdom. METHODS: Two systematic literature reviews of the bibliographic database Medline were performed in order to identify relevant publications (of year 2000+) on administration costs of chemotherapy for the treatment of NSCLC. The review was supplemented by a search in the databases of the Cochrane Library, EMA-EPAR, and ClinicalTrial.GOV. In addition, treatment guidelines, reimbursement databases, and national reimbursement tariffs were hand-searched. Semi-structured interviews with expert oncologists were completed. Data extraction and evidence synthesis from these sources formed the basis of this evaluation. RESULTS: Twenty-three manuscripts, 108 phase III study protocols, 6 EMA-labels, and 12 European treatment guidelines were included in the analysis. The ten NSCLC antineoplastic drugs mentioned in the ESMO and NCCN guidelines cover a wide set of administration patterns with respect to 1st or 2nd line monotherapy, combination therapy, and mono-or combination-maintenance therapy. The treatment schedules vary in dose per application, composition per cycle, and number of cycles. The main tariff for France is GHS 9606/GHM 28Z07Z (€386), for Germany daycase DRG 71B (€720) and several separate agreements (“Onkologievereinbarung”) and for the UK daycase HRG SB97Z+SB13Z (£399). For Italy and Spain the actual DRG values vary tremendously, for instance in Italy for DRG410 (€310 for Emilia Romagna vs. €40 for Basilicata), and in Spain C.6 for Galicia (€170) or 1.7.2.2 for Asturia (€149). CONCLUSIONS: The difference in treatment schedules in combination with the variation in national administration tariffs shows the importance of a sensitivity analysis when conducting a health economic analysis of NSCLC administration costs in Europe.